Sigyn Therapeutics, Inc. (OTCQB: SIGY) CEO Jim Joyce issued a shareholder update on March 13, 2026, detailing the company's strategic initiatives, including a potential merger with a Nasdaq-listed company at risk of not meeting the $5 million minimum market value of listed securities (MVLS) requirement and the sale of certain assets. The update also provides an overview of Sigyn's therapeutic pipeline, emphasizing CardioDialysis, a device designed to treat cardiovascular disease by reducing cholesterol-transporting lipoproteins and inflammatory molecules.
Joyce, who previously founded Aethlon Medical and led the development of the Hemopurifier, highlighted the challenges Sigyn has faced in capitalizing its operations. The company went public through a merger with an established OTC company but failed to execute an uplist to Nasdaq due to a regulatory catch-22: Nasdaq required review of investors before an effective SEC registration statement, while SEC required Nasdaq listing approval before deeming the registration statement effective. As a result, Sigyn withdrew its registration statement.
Despite these setbacks, Joyce emphasized the potential of CardioDialysis, which targets cardiovascular disease, the leading cause of death globally. Unlike lipoprotein apheresis devices limited to fewer than 60 specialized centers in the U.S., CardioDialysis is designed for use on dialysis machines at over 7,500 clinics. The device also targets inflammatory molecules relevant to sepsis, traumatic brain injury (TBI), and other conditions. Joyce noted that the TBI indication has emerged as a valuable asset that the company hopes to leverage through a strategic transaction.
Regarding sepsis, Joyce pointed out that there is no approved therapy, and the leading candidate, the PMX hemoadsorption device from Spectral Medical (TSX: TSX), has a market value of approximately $300 million. He encouraged shareholders to follow Spectral Medical, noting that CardioDialysis has been validated to reduce sepsis-inducing bacterial toxins and inflammatory mediators.
The update also included a link to Joyce's previous January 15th shareholder update, which outlines strategies to reduce shareholder dilution. The company has 2,330,042 shares outstanding as of March 11, 2026. Joyce can be reached at jj@sigyntherapeutics.com for further inquiries.
For more information about Sigyn Therapeutics and its development pipeline, including ImmunePrep for cancer immunotherapy, ChemoPrep for targeted chemotherapy delivery, and ChemoPure to reduce chemotherapy toxicity, visit www.SigynTherapeutics.com.
